Categories AlphaGraphs, Earnings, Health Care

Vertex Pharma (VRTX) expands cystic fibrosis pipeline; raises FY21 outlook

Biotechnology company Vertex Pharmaceuticals (NASDAQ: VRTX) has reported higher earnings and revenues for the third quarter of 2021. The bottom line also exceeded Wall Street’s projection amid a 29% growth in revenues. The management has raised its full-year outlook for product revenue, citing the continued expansion of the company’s cystic fibrosis drug pipeline.

Third-quarter earnings, on an adjusted basis, rose sharply to $3.56 per share from $2.64 per share in the corresponding period of last year. The number also came in above analysts’ forecast. Unadjusted net income was $851.9 million or $3.28 per share, compared to $667.4 million or $2.53 per share in the third quarter of 2020.

Vertex Pharmaceuticals Q3 2021 earnings infographic

The impressive earnings performance reflects a 29% increase in revenues to $1.98 billion. Market watchers were looking for slower growth. The top-line benefitted from the continued expansion of the company’s pipeline in cystic fibrosis and incremental investment to support the launches of medicines globally.

“Our financial performance in the third quarter was outstanding, marked by the exceptional continued growth of TRIKAFTA/KAFTRIO. Based on these results, we are again raising our 2021 product revenue guidance, and we see significant additional growth ahead as we continue to deliver this transformational medicine to more people with CF,” said Reshma Kewalramani, CEO of Vertex.


Read management/analysts’ comments on quarterly results


VRTX’s shares have made strong gains after the recent earnings announcement but lost momentum since then. In the past twelve months, the stock has lost about 42%.

Prior Performance

  • Vertex Pharma Q1 2021 earnings
  • Vertex Pharmaceuticals Q3 2019 Earnings Infographic

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Infographic: Key highlights from Kohl’s Corporation’s (KSS) Q1 2022 earnings results

Kohl’s Corporation (NYSE: KSS) reported first quarter 2022 earnings results today. Total revenue decreased 4.4% year-over-year to $3.7 billion. Reported net income amounted to $14 million, or $0.11 per share,

Foot Locker (FL) bets on diversification to maintain sales. Is the stock a buy?

Foot Locker, Inc.  (NYSE: FL) is a highly sought-after sportswear retailer, offering a wide range of products including sneakers and athletic apparel. Like most traditional store operators, the company is

Cisco (CSCO) Earnings: Q3 2022 profit beats estimates

Cisco Systems Inc. (NASDAQ: CSCO) published third-quarter results Wednesday after the closing bell, reporting higher earnings and flat revenues. Third-quarter adjusted earnings rose to $0.87 per share from $0.83 per

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top